Shares Of CTI Biopharma Corp. (CTIC) Have Risen Above Previo...| MENAFN.COM

Friday, 19 August 2022 04:22 GMT

Shares Of CTI Biopharma Corp. (CTIC) Have Risen Above Previous 52-Week High

(MENAFN- Investor Brand Network)

CTI BioPharma Corp. (NASDAQ:CTIC) traded at a new 52-week high today of $7.79. This new high was reached on below average trading volume as 410,000 shares traded hands, while the average 30-day volume is approximately 4.4 million shares.

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

In the past 52 weeks, CTI BioPharma Corp. share prices are bracketed by a low of $1.43 and a high of $7.79 and is now at $7.68, 437% above that low price.

Based on a current price of $7.68, CTI BioPharma Corp. is currently 19.2% above its average consensus analyst price target of $6.21.

Receive IBN Spotlights –“Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights , please visit 

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years . Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series . With a proven track record serving 500+ client partners , IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.